Merck & Co., Inc. (NYSE:MRK)

Big Pharma Short Sellers Hike Their Bets

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

How Dow 28,000 Can Rapidly Become Dow 30,000 and Even Higher in 2020

Investors love seeing the stock market hit new highs. It's impressive enough for the Dow Jones industrial average to have hit 28,000 and for the S&P 500 to have hit ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

As the Dow Hits All-Time High, Over Half of Dow Stocks Keep Disappointing Investors

When investors hear that the stock market just hit a new all-time high, it's probably fairly easy to assume that this means almost all the individual stocks are probably at ...
Read Full Story »

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) reported their most recent quarterly results before the opening bell Tuesday. Despite some trepidation for the health care sector, ...
Read Full Story »

Merck and Pfizer Earnings: What to Expect

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Apple, Chevron, Exxon, Pfizer and More Dow Earnings Coming This Week

Six of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. The Dow is just off its all-time high, while earnings season ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

How Biotech and Big Pharma Have Upside Heading Into Earnings

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Abbott Labs, CSX, IBM, Netflix, Occidental, Whiting, Amgen, Gilead, Merck, Pfizer and More

Stocks were indicated to open marginally higher on Thursday as the world appears to have better hopes for a Brexit framework out of Europe. Investors are having to grapple with ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

FDA Accepts for Review the Newest Treatment for C Diff

Merck & Co. Inc. (NYSE: MRK) has just announced that the U.S. Food and Drug Administration (FDA) accepted a couple New Drug Applications (NDAs) for review. Specifically, the FDA accepted ...
Read Full Story »

Why Dividend-Paying Large-Cap Pharmaceuticals Could Shine in Q4

With the final quarter of 2019 beginning next Tuesday, many investors are taking a long hard look at their portfolios and trying to make some adjustments. While the end of ...
Read Full Story »

Short Sellers Grow More Selective in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

4 Conservative Merrill Lynch US 1 Stock Picks That Pay Reliable Dividends

You can sense that the market is getting nervous. Technicians are noting the failure to break out to new highs, in addition to the fact that we are in the ...
Read Full Story »